Presence of Subclinical Atherosclerosis Is Marker of Mortality and Its Progression Increases Risk of Death

EMBARGOED UNTIL MONDAY, SEPTEMBER 30, 2PM EST  

Contact:  Ilana Nikravesh 
                Mount Sinai Press Office       
                212-241-9200    
               [email protected]        

Presence of Subclinical Atherosclerosis Is Marker of Mortality and Its Progression Increases Risk of Death
Mount Sinai study also shows imaging for early detection and monitoring can improve prediction and prevention of premature death

Newswise — (New York, NY – September 30, 2024)  - The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount Sinai Fuster Heart Hospital, published September 30 in the Journal of the American College of Cardiology.

This research is also the first to show that advanced imaging can detect atherosclerotic disease of the large vessels long before the appearance of symptoms—an approach that could be used worldwide to prevent cardiovascular disease and risk of death. Together, the findings emphasize the importance of early detection of atherosclerosis.

“The long asymptomatic phase of the disease presents a window of opportunity that has not been exploited in the younger population,” says lead author Valentin Fuster, MD, PhD, President of Mount Sinai Fuster Heart Hospital and General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). 

Atherosclerosis is a disease in which lipids, such as cholesterol, and other substances accumulate in plaques on the arterial wall, causing the vessels to harden and narrow, and increasing the risk of severe cardiovascular conditions. Subclinical atherosclerosis is a common condition in which these plaques are present in an artery without causing any symptoms or signs of disease. It can affect people of any age and can lead to serious health conditions including stroke, heart attack, and chronic limb-threatening ischemia.

Despite advances in cardiovascular research, it has remained unclear whether the risk of death from all causes in asymptomatic individuals can be predicted by monitoring the extent and progression of atherosclerosis, especially in the carotid arteries, which supply blood to the brain. 

The goal of the new study, called the BioImage project—a collaboration between Mount Sinai and the CNIC—was to determine the independent predictive value of the burden and progression of subclinical atherosclerosis above and beyond what can be predicted using established cardiovascular risk factors.

The study included 5,716 asymptomatic U.S. adults with an average age of 69 years (56.7% women) who were examined from 2008 to 2009. The study participants were examined with two imaging techniques. Atherosclerotic plaques in the carotid arteries were measured with vascular ultrasound, which allows detailed visualization of the interior of blood vessels, and calcification of the coronary arteries was assessed by computed tomography.

A subset of 732 study participants underwent a second vascular ultrasound scan more than eight years after the initial examination. All participants were followed up to determine the rate of death from any cause, the main outcome measure of the study.

Over the 12.4 years of follow-up, 901 (16%) of the participants died. Carotid plaque burden and coronary artery calcification measured at the start of the study were both associated with death from any cause. Moreover, progression of carotid atherosclerosis provided further prognostic information and was independently associated with all-cause mortality. 

“Vascular ultrasound is a non-invasive and affordable test, and the valuable prognostic information it provides can be used to improve risk stratification and to target lifestyle recommendations for the control of cardiovascular risk factors,” explains Borja Ibáñez, PhD, Scientific Director of the CNIC.

The study concluded that detecting subclinical atherosclerosis early and monitoring its progression can improve the prediction and prevention of death from any cause, offering a valuable tool for clinical practice.

Mount Sinai Is a World Leader in Cardiology and Heart Surgery 

Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital ranks No. 1 in New York and No. 4 nationally for cardiology, heart, and vascular surgery, according to U.S. News & World Report®. It also ranks No. 1 in New York and No. 6 globally according to Newsweek’s “The World’s Best Specialized Hospitals.”  

It is part of Mount Sinai Health System, which is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 9,000 primary and specialty care physicians; 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 39 multidisciplinary research, educational, and clinical institutes. Hospitals within the Health System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report's® “Best Hospitals” Honor Roll for 2024-2025. 

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

About the CNIC

The CNIC is an affiliate center of the Carlos III Health Institute (ISCIII), an executive agency of the Spanish Ministry of Science, Innovation, and Universities. Directed by Dr. Valentín Fuster, the CNIC is dedicated to cardiovascular research and the translation of the knowledge gained into real benefits for patients. The CNIC has been recognized by the Spanish government as a Severo Ochoa center of excellence (award CEX2020-001041-S, funded by MICIN/AEI/10.13039/501100011033). The center is financed through a pioneering public-private partnership between the government (through the ISCIII) and the Pro CNIC Foundation, which brings together 11 of the most important Spanish private companies.